Biomarker Guided Therapy in Chronic Heart Failure
Hans-Peter Brunner-La Rocca1, Sema Bektas1
1Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Cardiac Failure Review
|August 9, 2017
Summary
Biomarker-guided therapy using natriuretic peptides (BNP, NT-proBNP) shows promise for chronic heart failure, but more research is needed for clinical implementation. Current evidence is inconclusive, highlighting gaps in knowledge for effective treatment guidance.
Area of Science:
- Cardiology
- Biomarker Research
- Clinical Trials
Background:
- Natriuretic peptides (BNP, NT-proBNP) are established for acute heart failure diagnosis and prognosis.
- Their role in guiding chronic heart failure therapy remains uncertain, reflected in differing clinical guidelines.
- Other emerging biomarkers like galectin-3 and soluble ST2 show potential but require further investigation.
Purpose of the Study:
- To review the evidence on using natriuretic peptides for chronic heart failure therapy guidance.
- To analyze trial shortcomings and interpret existing results.
- To identify future research directions for biomarker-guided heart failure management.
Main Methods:
- Review of existing literature and meta-analyses on natriuretic peptide-guided heart failure trials.
- Analysis of guideline recommendations from European and American bodies.
- Examination of post-hoc analyses for emerging biomarkers.
Main Results:
- Evidence for natriuretic peptide-guided chronic heart failure therapy is inconclusive despite positive meta-analyses of smaller trials.
- Discrepancies in guideline recommendations highlight the uncertainty surrounding their therapeutic application.
- Emerging biomarkers show potential but lack prospective validation for guiding chronic heart failure treatment.
Conclusions:
- The clinical implementation of biomarker-guided therapy in chronic heart failure requires further robust evidence.
- Addressing current knowledge gaps through well-designed trials is crucial for optimizing heart failure management.
- Future research should focus on prospective studies for emerging biomarkers to confirm their therapeutic utility.
More Related Videos
Related Concept Videos
01:30Heart Failure V: Medical Management
400
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
400
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:22Heart Failure VI: Adjunct Therapies
442
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
442
01:22Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
467
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
467
01:30Cardiomyopathy II: Dilated Cardiomyopathy
649
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
649